Authors and Disclosures
Lawson Eng, MD, SM1,2, Rinku Sutradhar, PhD3,4, Yue Niu, MSc3, Ning Liu, PhD3, Ying Liu, MSc3, Yosuf Kaliwal, MSc3, Melanie L. Powis, MSc1, Geoffrey Liu, MD, MSc1,2, Jeffrey M. Peppercorn, MD, MPH5, Philippe L. Bedard, MD1,2 and Monika K. Krzyzanowska, MD, MPH1–3
1Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
2Divison of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
3Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
4Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
5Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Corresponding Author
Lawson Eng, MD, SM, Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Toronto, ON M5G 2M9, Canada; e-mail: Lawson.eng@utoronto.ca.
Authors' Disclosures of Potential Conflicts of Interest
Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I 5 Immediate Family Member, Inst 5 My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Geoffrey Liu
Honoraria: Pfizer, novartis, Merck, AstraZeneca, Takeda, AbbVie, Bayer, Bristol Myers Squibb, Roche Canada, Jazz Pharmaceuticals, Amgen
Consulting or Advisory Role: Pfizer, Novartis, AstraZeneca/MedImmune, Takeda, Roche Canada
Speakers' Bureau: AstraZeneca, Takeda, Pfizer
Research Funding: Roche (Inst), AstraZeneca/MedImmune (Inst), Takeda, Boehringer Ingelheim
Jeffrey M. Peppercorn
Employment: GlaxoSmithKline
Stock and Other Ownership Interests: GlaxoSmithKline
Consulting or Advisory Role: Abbott Laboratories
Research Funding: Outcomes4Me
Philippe L. Bedard
Consulting or Advisory Role: BMS (Inst), Pfizer (Inst), Seattle Genetics, Lilly, Amgen, Merck, Gilead Sciences
Research Funding: Bristol Myers Squibb (Inst), Sanofi (Inst), AstraZeneca (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Nektar (Inst), Merck (Inst), Seattle Genetics (Inst), Immunomedics (Inst), Lilly (Inst), Amgen (Inst), Bicara Therapeutics (Inst), Zymeworks (Inst)
Monika K. Krzyzanowska
Consulting or Advisory Role: Eisai, Lilly, Ipsen, Bayer
Research Funding: Eisai (Inst), Exelixis (Inst), Lilly (Inst)
No other potential conflicts of interest were reported.
Author Contributions
Conception and design: Lawson Eng, Melanie L. Powis, Philippe L. Bedard, Monika K. Krzyzanowska
Financial support: Lawson Eng, Monika K. Krzyzanowska
Administrative support: Monika K. Krzyzanowska
Provision of study materials or patients: Ying Liu, Geoffrey Liu
Collection and assembly of data: Lawson Eng
Data analysis and interpretation: Lawson Eng, Rinku Sutradhar, Yue Niu, Ning Liu, Ying Liu, Yosuf Kaliwal, Geoffrey Liu, Jeffrey M. Peppercorn, Philippe L. Bedard, Monika K. Krzyzanowska
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors